alpha-Methyldopa and depression: a clinical study and review of the literature
Abstract
A review of the literature showed that a high incidence or prevalence of depression in patients being treated with alpha-methyldopa has never been documented. In their study of hypertensive patients in a general medical clinic the authors found that symptoms of depression were no more common in 42 patients treated with alpha-methyldopa than in 38 patients treated with other antihypertensive agents. As with other centrally active agents, alpha-methyldopa appears able to produce many different behavioral symptoms, including mood changes, in predisposed individuals. Because alpha-methyldopa is a DOPA decarboxylase inhibitor but does not consistently affect mood or induce depression, its effects do not support a catecholamine hypothesis of depression.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
